Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Found 1 result for Related Articles by Review for PMID: 32119371
Filters applied. Clear filters
Book

Erlotinib

Jake Carter, Prasanna Tadi  1
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Erlotinib

Jake Carter et al.
Free Books & Documents

Excerpt

Erlotinib is a tyrosine kinase receptor inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer and advanced pancreatic cancer. This drug inhibits the epidermal growth factor receptor (EGFR), affecting both wild-type and mutated EGFRs, which are crucial in cellular differentiation, proliferation, and angiogenesis. Erlotinib’s efficacy is influenced by proper patient selection based on thorough diagnostic evaluation. The drug has a narrow therapeutic index, and its use is associated with adverse effects such as diarrhea and rash.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Jake Carter declares no relevant financial relationships with ineligible companies.

Disclosure: Prasanna Tadi declares no relevant financial relationships with ineligible companies.

Similar articles

  • Cosmeceuticals.
    Pandey A, Jatana GK, Sonthalia S. Pandey A, et al. 2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31334943 Free Books & Documents.
  • Gadolinium Magnetic Resonance Imaging.
    Ibrahim MA, Hazhirkarzar B, Dublin AB. Ibrahim MA, et al. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 29494094 Free Books & Documents.
  • Erlotinib-induced Perioral Lesions Resembling Scleroderma.
    Dasanu CA, Alvarez-Argote J, Dasanu RG, Soliman A, Codreanu I. Dasanu CA, et al. Acta Dermatovenerol Croat. 2024 Nov;32(2):118-119. Acta Dermatovenerol Croat. 2024. PMID: 39803739
  • Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.
    Salisbury L, Baraitser L. Salisbury L, et al. In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5. In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5. PMID: 36137063 Free Books & Documents. Review.
  • Adenosine Deaminase Deficiency.
    Hershfield M, Tarrant T. Hershfield M, et al. 2006 Oct 3 [updated 2024 Mar 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2006 Oct 3 [updated 2024 Mar 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301656 Free Books & Documents. Review.
See all similar articles

References

    1. Azzoli CG, Temin S, Giaccone G. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract. 2012 Jan;8(1):63-6. - PMC - PubMed
    1. Bulbul A, Husain H. First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option? Front Oncol. 2018;8:94. - PMC - PubMed
    1. Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635. - PubMed
    1. Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, Wang ZH. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Des Devel Ther. 2016;10:1961-72. - PMC - PubMed
    1. Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 01;27(34):5788-93. - PMC - PubMed

Publication types

LinkOut - more resources